XML 34 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Statements of Operations (Unaudited) (USD $)
 3 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Revenues:        
License fee and milestone revenue $ 20,907 $ 26,456 $ 45,745 $ 52,824
License fee and milestone revenue from affiliated entity 106,250 105,208 212,500 198,958
Grant and miscellaneous revenue 308,925 2,288,099 1,870,958 5,273,246
Total revenues 436,082 2,419,763 2,129,203 5,525,028
Operating expenses:        
Research and development 4,527,086 4,463,978 8,569,665 8,885,777
General and administrative 2,696,909 3,092,386 5,184,997 6,411,618
Gain on sale of assets     (651,000) (250,000)
Total operating expenses 7,223,995 7,556,364 13,103,662 15,047,395
Loss from operations (6,787,913) (5,136,601) (10,974,459) (9,522,367)
Other income (expense):        
Interest and other income, net 41,036 7,799 72,580 9,654
Change in fair value of common stock warrants 3,594,782 4,898,758 46,609 7,230,626
Loss from investment in affiliated entity (992,373) (2,607,227) (1,553,917) (2,977,238)
Net loss (4,144,468) (2,837,271) (12,409,187) (5,259,325)
Net loss attributable to non-controlling interest 11,289 15,112 21,059 24,553
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (4,133,179) $ (2,822,159) $ (12,388,128) $ (5,234,772)
Loss per common share - basic and diluted:        
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders $ (0.03) $ (0.02) $ (0.09) $ (0.04)
Weighted average number of common shares outstanding - basic and diluted 134,968,394 127,256,364 134,968,394 124,124,645